Anebulo Pharmaceuticals Correlations
ANEB Stock | USD 1.59 0.05 3.25% |
The current 90-days correlation between Anebulo Pharmaceuticals and Aerovate Therapeutics is 0.06 (i.e., Significant diversification). The correlation of Anebulo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Anebulo Pharmaceuticals Correlation With Market
Average diversification
The correlation between Anebulo Pharmaceuticals and DJI is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Anebulo Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Anebulo |
Moving together with Anebulo Stock
0.61 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
0.63 | NKTX | Nkarta Inc | PairCorr |
0.63 | ACET | Adicet Bio | PairCorr |
Moving against Anebulo Stock
0.44 | BMY | Bristol Myers Squibb Earnings Call This Week | PairCorr |
0.36 | MDGL | Madrigal Pharmaceuticals | PairCorr |
0.48 | PTCT | PTC Therapeutics | PairCorr |
0.61 | TGNA | Tegna Inc | PairCorr |
0.5 | DNOW | Now Inc | PairCorr |
0.48 | FNMFO | Federal National Mortgage | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Anebulo Stock performing well and Anebulo Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Anebulo Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
ADAG | 3.72 | (0.52) | 0.00 | 2.80 | 0.00 | 5.26 | 41.45 | |||
ACRV | 3.44 | (0.49) | 0.00 | (0.33) | 0.00 | 8.45 | 26.67 | |||
ANAB | 4.34 | (0.82) | 0.00 | (0.41) | 0.00 | 8.22 | 44.55 | |||
MLYS | 3.50 | (0.38) | 0.00 | (0.52) | 0.00 | 7.79 | 26.52 | |||
AVTE | 1.98 | 0.37 | 0.15 | 8.85 | 1.55 | 5.53 | 18.16 | |||
OPT | 3.29 | 0.41 | 0.10 | 0.58 | 3.78 | 8.28 | 17.06 | |||
ANTX | 2.98 | 0.15 | 0.05 | 0.23 | 2.55 | 8.94 | 28.89 | |||
PMVP | 1.86 | (0.17) | 0.00 | (0.70) | 0.00 | 4.35 | 12.59 | |||
MOLN | 3.37 | (0.15) | 0.00 | (0.33) | 0.00 | 8.43 | 23.47 |
Anebulo Pharmaceuticals Corporate Management
Rex CFA | CFO Sec | Profile | |
Daniel George | Acting Officer | Profile | |
Scott Anderson | Head Affairs | Profile | |
Kenneth Cundy | Chief Officer | Profile |